Advicenne’s Lead Candidate Approved for Orphan Drug Designation in the Treatment of Cystinuria in Europe
December 18, 2019
Nîmes, France, December 18, 2019 – 5:45 CET – Advicenne (Euronext : ADVIC – FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, today announced that its lead drug candidate, ADV7103, has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of cystinuria in Europe.